India, March 6 -- Shares of Scienture Holdings, Inc. (SCNX) jumped over 28% on Thursday morning after the company announced its plans to commercially launch Rezenopy, a life-saving opioid overdose emergency treatment through a collaboration with Kindeva Drug Delivery L.P.
SCNX is currently trading at $2.8400, up $0.6300 or 28.3784%, on a huge volume of 40 million shares, above average volume of 10 thousand, on the Nasdaq. The stock opened its trading at $3.2500 after closing Wednesday at $2.2100. Over the past 52-week period, the stock has traded between $2.0090 and $44.5600.
The company said that its wholly owned subsidiary, Scienture, LLC, has agreed with Summit Biosciences Inc., a wholly owned subsidiary of Kindeva Drug Delivery L.P., ...